Search clinical trials for: C-11 acetate

Total 27909 results

Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Epilepsy
Bial - Portela C S.A.

Completed

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Epilepsy

United States
Bial - Portela C S.A.

Completed

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Partial Epilepsy

Belgium
Bial - Portela C S.A.

Completed

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Epilepsy

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia

Postherpetic Neuralgia
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Bial - Portela C S.A.

Terminated

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Epilepsy

Portugal
Cardica, Inc

Completed

Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device

Heart Disease

United States
IRCCS Fondazione Stella Maris

Completed

Testing Miglustat Administration in Subjects With Spastic Paraplegia 11 (TreatSPG11)

Hereditary Spastic Paraparesis

Italy
Cartesian Therapeutics

Active, not recruiting

Descartes-11 in Multiple Myeloma

Multiple Myeloma

United States
CHDI Foundation, Inc.
Universitaire Ziekenhuizen KU Leuven

Terminated

iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626

Huntington Disease

Belgium
Check-Cap Ltd.

Completed

Evaluation C-Scan System in Providing Structural Information and Polypoid Lesions in the Colon of Healthy Subjects (CRC)

Risk for Colorectal Cancer

Israel
Insel Gruppe AG, University Hospital Bern

Active, not recruiting

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

Prostate Cancer

Switzerland
Novartis Pharmaceuticals

Completed

Study of Diagnostic Performance of [18F]CTT1057 in BCR (GuidePath)

Recurrence | Prostatic Neoplasms | Prostate Cancer

Spain, France, Switzerland, United States
National Institute on Drug Abuse (NIDA)

Unknown

Cognitive Correlates of Substance Abuse - 11

Amphetamine-Related Disorders

United States
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11) (CASTLE-11)

Solid Tumor, Adult

China
Seoul National University Hospital

Completed

Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 (HN17-11)

Recurrent or Metastatic Nasopharyngeal Carcinom

Korea, Republic of
Karadeniz Technical University

Completed

First Trimester Fetal Thymus Volume May Predict Preeclampsia

Preeclampsia

Turkey
Nuwellis, Inc.

Terminated

C-Pulse Implantable Counterpulsation Pump (ICP) - A Heart Assist Device

Heart Failure

Canada
Università Vita-Salute San Raffaele

Recruiting

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients. (ANH)

C.Surgical Procedure; Cardiac

Singapore, Saudi Arabia, Italy, Russian Federation, Serbia, Thailand
Clinton Bahler

Completed

The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer

Prostate Cancer

United States
University of Copenhagen

Recruiting

Human Auto-ethanol Formation and Acetate Signaling (HotFacets)

Healthy

Denmark
Phoenix Molecular Imaging

Completed

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Prostate Cancer | Prostate Adenocarcinoma

United States
JOSE IVAN RODRIGUEZ DE MOLINA SERRANO

Completed

LPP , MP and DP:Relation With Mortality and SOFA in Mechanically Ventilated Patients in ER, Ward and ICU (LUMEDRI-MORT)

Mechanical Ventilation Complication | Mechanical Power | Driving Pressure | Lung Protective Ventilation

Mexico
National Cancer Institute (NCI)

Completed

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Glioblastoma | Brain Cancer | Malignant Glioma | Gliosarcoma

United States
Danish Head and Neck Cancer Group

Completed

DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole

HNSCC,Larynx, Pharynx and Oral Cavity

Denmark
Hospital Universitario de Canarias

Unknown

Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D (NEFROVID2010)

Kidney Failure, Chronic | Disorder of Vitamin D

Spain
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours

Epilepsy

Romania, Slovakia
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Milton S. Hershey Medical Center
OpenBiome

Withdrawn

EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant (EGESTA)

C.Difficile Colitis

United States
AstraZeneca

Terminated

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Elevated High-sensitivity C-Reactive Protein (hsCRP)

United States, Brazil, Bulgaria, Poland, Russian Federation, South Africa, United Kingdom, Germany, Estonia, Romania, Denmark, Netherlands, Norway, Canada, Mexico, Belgium, Israel, Puerto Rico, Colombia, Argentina, Venezuela, Panama, Urugu... and more

3

Subscribe